替尔泊肽与2型糖尿病患者肌肉组成变化(SURPASS-3 MRI):一项随机、开放标签、平行组、3期试验的事后分析
SURPASS-3 MRI子研究的事后分析纳入246例2型糖尿病患者,比较替尔泊肽(5、10、15 mg)与德谷胰岛素治疗52周后大腿肌肉体积、肌肉体积Z评分和肌肉脂肪浸润的变化。替尔泊肽组肌肉脂肪浸润显著降低,肌肉体积和Z评分亦降低,肌肉体积变化与基于UK Biobank人群的体重变化相关估计相似,而肌肉脂肪浸润降低幅度大于人群估计。
要点
- 替尔泊肽治疗52周后肌肉脂肪浸润显著降低(合并组平均变化-0.36个百分点,95%CI -0.48至-0.25,p<0.0001)。
- 替尔泊肽组肌肉体积和肌肉体积Z评分显著降低,但肌肉体积变化与基于UK Biobank人群的体重变化相关估计相似(合并组平均差异-0.04 L,95%CI -0.11至0.03,p=0.22)。
- 替尔泊肽组肌肉脂肪浸润降低幅度显著大于人群估计(合并组平均差异-0.42个百分点,95%CI -0.54至-0.31,p<0.0001)。
核心结论
- 在SURPASS-3 MRI子研究中,替尔泊肽治疗与肌肉脂肪浸润的可能有益变化相关,肌肉体积降低与体重变化的一般关联大致一致。
- 这些发现提供了替尔泊肽对肌肉健康潜在影响的信息,可能有助于医疗保健提供者为个体患者选择治疗方案。
研究设计与样本
- SURPASS-3是一项随机、开放标签、平行组、3期试验,MRI子研究为多中心(45个中心)、多国(8个国家)研究。
- 纳入年龄≥18岁、胰岛素初治的2型糖尿病患者,接受二甲双胍联合或不联合SGLT-2抑制剂治疗,HbA1c 7.0-10.5%(53-91 mmol/mol),BMI≥25 kg/m2,脂肪肝指数≥60。
- 参与者按1:1:1:1随机分配至每周一次皮下注射替尔泊肽5、10或15 mg,或每日一次皮下注射滴定德谷胰岛素。
- 在基线和第52周通过MRI量化大腿肌肉脂肪浸润、肌肉体积和肌肉体积Z评分(与性别、身高、体重和BMI无关)。
- 事后分析采用配对t检验比较各组基线至第52周肌肉组成均值差异,采用校正ANCOVA模型比较合并替尔泊肽组与德谷胰岛素组肌肉组成变化差异,并与基于UK Biobank数据(n=2942)的多重线性回归模型估计的人群值比较。
主要发现
- 基线时总体平均年龄56.0岁(SD 9.9),2型糖尿病中位病程6.7年(IQR 3.7至10.7),平均HbA1c 8.3%(SD 0.9),平均BMI 33.4 kg/m2(SD 4.8),76例(30.9%)使用SGLT-2抑制剂。
- 合并替尔泊肽组与德谷胰岛素组基线平均肌肉脂肪浸润、肌肉体积和肌肉体积Z评分相似。
- 替尔泊肽合并组及各剂量组从基线至第52周肌肉脂肪浸润显著降低(合并组平均变化-0.36个百分点[95%CI -0.48至-0.25],p<0.0001),肌肉体积显著降低(-0.64 L[95%CI -0.74至-0.54],p<0.0001),肌肉体积Z评分显著降低(-0.22[95%CI -0.29至-0.15],p<0.0001),均伴随显著体重降低。
- 德谷胰岛素组体重和肌肉体积出现适度且显著的增加,其他变量无显著变化;合并替尔泊肽组三个肌肉组成变量的变化与德谷胰岛素组相比均有显著差异。
- 替尔泊肽各剂量组观察到的肌肉体积变化与人群估计变化相似(合并组平均差异-0.04 L[95%CI -0.11至0.03],p=0.22);而各剂量组肌肉脂肪浸润降低幅度显著大于人群估计(合并组平均差异-0.42个百分点[95%CI -0.54至-0.31],p<0.0001),替尔泊肽15 mg组肌肉体积Z评分降低幅度显著大于人群估计(平均差异-0.18[95%CI -0.29至-0.07],p=0.0016)。
临床怎么用
- 作者认为,这些发现提供了替尔泊肽对肌肉健康潜在影响的信息,可能有助于医疗保健提供者为个体患者选择治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Substantial weight reduction is often associated with loss of muscle mass. Tirzepatide has been associated with significant reductions in body weight in type 2 diabetes trials and a beneficial effect on body fat distribution in the SURPASS-3 MRI substudy. This post-hoc exploratory analysis studied the association of tirzepatide treatment with changes in thigh muscle volume, muscle volume Z score, and muscle fat infiltration, and aimed to contextualise the results using longitudinal MRI data from UK Biobank participants. METHODS: SURPASS-3 was a randomised, open-label, parallel-group, phase 3 trial. The multicentre (45 sites) and multinational (eight countries) MRI substudy of SURPASS-3 enrolled insulin-naive adults (aged ≥18 years) with type 2 diabetes who were on treatment with metformin with or without a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, had an HbA1c of 7·0-10·5% (53-91 mmol/mol), a BMI of at least 25 kg/m2, and a fatty liver index of at least 60. Participants were randomly assigned (1:1:1:1) to receive subcutaneous injection once per week of tirzepatide (5, 10, or 15 mg), or subcutaneous injection once per day of titrated insulin degludec. Thigh muscle fat infiltration, muscle volume, and muscle volume Z score (invariant to sex, height, weight, and BMI) were quantified by MRI at baseline and week 52. In this post-hoc analysis, we assessed the differences between mean baseline and week 52 muscle composition values in the tirzepatide groups (pooled 5 mg, 10 mg, and 15 mg group, and per dose group) and insulin degludec group using paired t tests, and the differences in muscle composition changes with pooled tirzepatide versus insulin degludec via adjusted ANCOVA models. Observed changes in muscle fat infiltration, muscle volume, and muscle volume Z scores were compared using paired t tests to population-based estimates calculated from multiple linear regression models fitted to UK Biobank data (n=2942), capturing associations with change in body weight. Analyses were done by modified intention to treat, in the participants enrolled in the MRI substudy with a valid MRI scan at week 52. The SURPASS-3 clinical trial is registered with ClinicalTrials.gov, NCT03882970, and is complete. FINDINGS: Participants were assessed for eligibility and recruited from April 1, 2019, to Nov 15, 2019. Among 502 participants assessed for eligibility to participate in the MRI substudy, 296 were enrolled, and 246 had a valid week 52 MRI scan and were included in the post-hoc analyses (tirzepatide 5 mg, n=63; tirzepatide 10 mg, n=60; tirzepatide 15 mg, n=67; insulin degludec, n=56; 147 [59·8%] male participants and 99 [40·2%] female participants). At baseline, overall mean age was 56·0 years (SD 9·9), median duration of type 2 diabetes was 6·7 years (IQR 3·7 to 10·7), mean HbA1c was 8·3% (SD 0·9), mean BMI was 33·4 kg/m2 (SD 4·8), and 76 (30·9%) were on an SGLT-2 inhibitor. Mean baseline muscle fat infiltration, muscle volume, and muscle volume Z scores were similar between the pooled tirzepatide group and insulin degludec group. For the pooled and individual tirzepatide dose groups, significant reductions were observed from baseline to week 52 in muscle fat infiltration (for pooled tirzepatide, mean change -0·36 percentage points [95% CI -0·48 to -0·25], p<0·0001), muscle volume (-0·64 L [95% CI -0·74 to -0·54], p<0·0001), and muscle volume Z score (-0·22 [95% CI -0·29 to -0·15], p<0·0001), which occurred in the context of significant weight reduction. Insulin degludec was associated with a modest and significant increase in bodyweight and muscle volume, but no significant change in the other variables. The changes in all three muscle composition variables with pooled tirzepatide were significantly different compared to those with insulin degludec. In tirzepatide-treated participants, observed muscle volume changes across all tirzepatide doses were similar to population-based estimated changes (for pooled tirzepatide, mean difference vs population-based estimate, -0·04 L [95% CI -0·11 to 0·03], p=0·22); whereas, observed reductions in muscle fat infiltration across all doses were significantly greater than population-based estimates (for pooled tirzepatide, mean difference -0·42 percentage points [95% CI -0·54 to -0·31], p<0·0001), and the observed reduction in muscle volume Z score with tirzepatide 15 mg was significantly greater than the population-based estimate (mean difference -0·18 [95% CI -0·29 to -0·07], p=0·0016). INTERPRETATION: In the SURPASS-3 MRI substudy, in the context of significant improvements in bodyweight and fat distribution, tirzepatide treatment was associated with potentially favourable changes in muscle fat infiltration and reductions in muscle volume broadly in accordance with the general association between changes in muscle volume and bodyweight. The present findings provide additional information on the potential effect of tirzepatide on muscle health that might help health-care providers when deciding among treatment options for individual patients. FUNDING: Eli Lilly and Company.
引用
- Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2025. PMID: 40318682. doi:10.1016/S2213-8587(25)00027-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。